EUCTR2006-000591-33-GB进行中（未招募）不适用
A Phase II study of Gemcitabine and Bexarotene (GemBex) in the treatment of cutaneous T-cell lymphoma - GemBex
niversity College London0 个研究点目标入组 84 人开始时间: 2006年3月10日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males or non-pregnant females aged 18 years or over
- •2. Histologically confirmed diagnosis of CTCL, including mycosis fungoides and Sézary syndrome.
- •3. Patients with CTCL stages Ib, IIa, IIb, III, IVa and IVb. Staging is to take place within 1 month of obtaining full written informed consent.
- •4. Patients who have failed standard skin-directed therapy and have had at least 1 course of prior systemic therapy, such as interferon, chemotherapy, Denileukin diftitox which they have either failed to respond to or have subsequently progressed.
- •5. Anticipated life expectancy greater than six months.
- •6. Written informed consent to participate in the study
- •7. Bexarotene naive or previous response to single-agent bexarotene, but at least 3 months since last treatment with bexarotene
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. ECOG Performance Status >1
- •2. Patients who have not received at least 1 course of prior systemic therapy for CTCL.
- •3. CD30+ (Ki1+ve) anaplastic large cell lymphoma
- •4. Patients who have failed previous treatment with bexarotene
- •5. Patients who have previously experienced a severe adverse reaction to bexarotene
- •6. Concomitant use of any anti-cancer therapy.
- •7. Concomitant use of any investigational agent.
- •8. Use of any investigational agent within 4 weeks of study entry.
- •9. Clinically significant active infection.
- •10. Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
- •11. Excessive alcohol consumption. To minimise the risk of pancreatitis secondary to hyperlipidaemia due to Bexarotene
- •12. Uncontrolled diabetes mellitus. To minimise the risk of pancreatitis secondary to hyperlipidaemia due to Bexarotene
- •13. Biliary tract disease. To minimise the risk of pancreatitis secondary to hyperlipidaemia due to Bexarotene
- •14. History of pancreatitis. To minimise the risk of pancreatitis secondary to hyperlipidaemia due to Bexarotene
- •15. Concomitant drug therapy with other medications that can elevate triglycerides or cause pancreatic toxicity e.g. Gemfibrozil. Due to incidence of hyperlipidaemia secondary to Bexarotene.
- •16. Inadequate bone marrow or other organ function, as evidenced by:
- •Unsupported haemoglobin <9.0 g/dL (transfusions and/or erythropoietin are permitted); Absolute neutrophil count (ANC) <1.5 x 109/L; Platelet count <100 x 109/L;
- •17. Total bilirubin >1.25 x upper limit of normal (ULN) for institution, aspartate transaminase/glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/ glutamic pyruvic transaminase (ALT/SGPT) >2.0 x ULN, serum creatinine >2 x ULN for age and sex
- •18. Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin or cervical epithelial neoplasm [CIN1, carcinoma in situ] that has been treated curatively).
- •19. Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures.
- •20. Patients who are pregnant or breast-feeding (all women of child bearing potential must use the contraceptive pill or intrauterine contraceptive device (IUCD) during the treatment period and for at least 1 month thereafter). Male patients must use a barrier method of contraception during the treatment period and for at least 1 month thereafter.
- •21. Any treatment for lymphoma, including photopheresis, within the 4 weeks prior to entering the study. For patients receiving long-term corticosteroid therapy, the dose should ideally be stopped and if this is not feasible reduced to as low as possible. If steroids cannot be stopped, patients who have been on stable doses less than or equal to 20mg for at least 3 months can be entered into the study. Local radiotherapy to isolated symptomatic tumour nodules requiring immediate treatment maybe given until 2 weeks prior to entering the study.
- •22. Warfarin
研究者
相似试验
招募中
2 期
A Phase II study of Gemcitabine, Cisplatin and Bevacizumab for the patients with first recurrent and refractory ovarian clear cell carcinomaJPRN-UMIN000051087Kansai Clinical Oncology Group(KCOG)28
已完成
2 期
Phase 2 study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) therapy for refractory/relapsed malignant lymphoma.malignant lymphomaJPRN-UMIN000011682TOHOKU HEMATOLOGY FORUM30
进行中（未招募）
2 期
GHG-GCDrelapsed or refractory non-Hodgkin's lymphomaJPRN-jRCT1041230085Tsurumi Hisashi20
招募中
2 期
Phase II study of gemcitabine, carboplatin and dexamethasone with or without rituximab for patients with relapsed or refractory non-Hodgkin's lymphomarelapsed or refractory non-Hodgkin's lymphomaJPRN-UMIN000015998Gifu University Hospital20
已完成
2 期
Phase II/III study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemotherapy for resectable pancreatic cancer (Prep-02/JSAP-05)JPRN-UMIN000009634Study group of preoperative therapy for pancreatic cancer (PREP)/Japanese Study Group of Adjuvant Therapy for pancreatic Cancer (JSAP)364